Protox Doses First Patient

Protox Therapeutics has announced the enrollment and successful dosing of the first patient in a Phase I clinical study evaluating their lead drug, PRX3O2, to treat localized recurrent prostate cancer. PRX3O2 is a targeted prodrug that turns into a potent anticancer agent once activated by the enzyme, prostate specific antigen (PSA), produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX3O2 destroys the cells by punching holes in the cell membrane.

In preclinical studies, PRX3O2 has been shown to selectively and potently kill PSA-producing cells without harming adjacent healthy tissues or organs. PRX3O2 has the potential to address the unmet needs of millions of men suffering from localized prostate cancer and enlarged prostates.

FDAnews Drug Pipeline Alert, 3 May 2006

Back to the top | Soul Mates | Medical Links | Monterey News | Feedback |